Valeant/Ackman Going Whole Hog On Zoetis As Plan B For Allergan?
This article was originally published in The Pink Sheet Daily
Valeant investment partner William Ackman takes a stake in animal health company Zoetis in what could be a move to change strategies as Allergan continues to oppose Valeant’s offer.
You may also be interested in...
Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.